A study to evaluate the efficacy of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not candidates for transplantation and have achieved partial response (PR) or complete response (CR).. This study was prematurely terminated by the sponsor in light of new unpublished data that rendered the current design of the study no longer clinically relevant. A study design with the control arm of no active treatment was no longer appropriate. The termination of the trial was not based on any safety concerns in the study. ...
mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:""""""""}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity. A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.[1]. The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas. The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer ...
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating acute lymphoblastic leukemia.. PURPOSE: This randomized clinical trial is studying the side effects of two combination chemotherapy regimens and to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia. ...
A multi-agent system (M.A.S.) is a computerized system composed of multiple interacting intelligent agents within an environment. Multi-agent systems can be used to solve problems that are difficult or impossible for an individual agent or a monolithic system to solve. Intelligence may include some methodic, functional, procedural approach, algorithmic search or reinforcement learning. Although there is considerable overlap, a multi-agent system is not always the same as an agent-based model (ABM). The goal of an ABM is to search for explanatory insight into the collective behavior of agents (which dont necessarily need to be "intelligent") obeying simple rules, typically in natural systems, rather than in solving specific practical or engineering problems. The terminology of ABM tends to be used more often in the sciences, and MAS in engineering and technology.[1] Topics where multi-agent systems research may deliver an appropriate approach include online trading,[2] disaster response,[3][4] ...
This study looks at how well how well pazopanib hydrochloride, (targeted chemotherapy), combination chemotherapy, and radiation therapy work compared to radiation therapy alone, or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas. ...
... is medication delivered to the body to eliminate cancer cells or greatly reduce their effect. It targets cells that divide rapidly, a characteristic of most cancer cells.. Chemotherapy, often used to support and enhance other cancer treatment modalaties, interferes with the division and reproduction of cells. If a cancer cell cannot reproduce, it eventually dies without another cell to replace it. Chemotherapy is usually administered orally or intravenously. Some types of chemotherapy are delivered daily over a prescribed period, while others are given weekly. Similarly, some chemotherapy infusion sessions last only a few minutes, while others take a full day.. Recent advances in chemotherapy treatment mean patients may not experience some of the common side effects previously associated with chemotherapy. For instance, not all treatments result in hair loss, weight gain, or nausea. Side effects of chemotherapy depend on the type and dose of chemotherapy received. Your physician may ...
Abstract Background: For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering 90Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine.
The goal of this clinical research study is to find out if switching from a standard chemotherapy combination to a more intensive experimental combination, based on imaging scans, will improve response to treatment in patients with Hodgkin lymphoma (HL). The safety of this experimental chemotherapy combination will also be studied.
The present study demonstrated the following three important clinical observations. First, the OS of the chemotherapy group was better than that of the BSC group in elderly patients with poor PS. Second, the number of treatment cycles had a larger impact on the survival benefit of chemotherapy than the decision/selection of either single-agent therapy or carboplatin-doublet therapy. Third, hypoalbuminemia was not only the risk factor for early termination of chemotherapy, but also the independent prognostic factor in the chemotherapy group.. The clinician-estimated PS is the most common method to evaluate physiologic reserve and functional status in NSCLC patients, and it is used to assess a patients tolerability against chemotherapy. In previous clinical trials conducted for elderly, advanced NSCLC patients, such as the ELVIS and IFCT-0501 trials [3, 4, 7], 20-30% of patients had a PS of 2, whereas almost no data were available for patients with PS ≥ 3. Given this, there is a general ...
Table of Contents. Table of Contents 2. List of Tables 7. List of Figures 8. Introduction 9. Global Markets Direct Report Coverage 9. Chemotherapy Induced Neutropenia Overview 10. Therapeutics Development 11. Pipeline Products for Chemotherapy Induced Neutropenia-Overview 11. Pipeline Products for Chemotherapy Induced Neutropenia-Comparative Analysis 12. Chemotherapy Induced Neutropenia-Therapeutics under Development by Companies 13. Chemotherapy Induced Neutropenia-Therapeutics under Investigation by Universities/Institutes 16. Chemotherapy Induced Neutropenia-Pipeline Products Glance 17. Late Stage Products 17. Clinical Stage Products 18. Early Stage Products 19. Unknown Stage Products 20. Chemotherapy Induced Neutropenia-Products under Development by Companies 21. Chemotherapy Induced Neutropenia-Products under Investigation by Universities/Institutes 24. Chemotherapy Induced Neutropenia-Companies Involved in Therapeutics Development 25. Bio-Ker s.r.l 25. Biogenomics Limited 26. Bolder ...
Chemotherapy is the use of anticancer drugs to treat cancer cells. Chemotherapy has been used for many years and is one of the most common treatments for cancer. In most cases, chemotherapy works by interfering with the cancer cells ability to grow or reproduce. Different groups of drugs work in different ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in combination with other treatments, such as radiation or surgery. Often, a combination of chemotherapy drugs is used to fight a specific cancer. Certain chemotherapy drugs may be given in a specific order depending on the type of cancer its being used to treat.. While chemotherapy can be quite effective in treating certain cancers, chemotherapy drugs reach all parts of the body, not just the cancer cells. Because of this, there may be many side effects during treatment. Being able to anticipate these side effects can help you and your child prepare and, in some cases, prevent these symptoms from ...
This trial is investigating the efficacy and tolerability of oxaliplatin [Eloxatin] in combination with capecitabine [Xeloda] in untreated patients with locally
Inclusion Criteria:. Histologically confirmed solid tumor malignancy for which platinum-based chemotherapy on a 21-day cycle or 14 day cycle is being recommended. Stage I of the trial: newly diagnosed disease for which neoadjuvant or adjuvant chemotherapy is planned in the curative setting, or metastatic disease. Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial- if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy. Stage I: subjects may have already received no more than 2 cycle of their platinum-based chemotherapy but should not have received other prior chemotherapy regimens with the exception of patients with metastatic disease who received neoadjuvant or adjuvant chemotherapy and that chemotherapy was completed , 6 months prior to enrollment. Stage II: subjects must have received no ...
Chemotherapy combinations commonly used in the treatment of metastatic colorectal cancer include: fluorouracil (5FU) and leucovorin (FU/LV) leucovorin c...
This phase Ib study will evaluate the antimalarial and transmission blocking activity of a single dose of DSM265 or OZ439 in healthy subjects with induced blood
Patients median age was 60 years (28-72). All were classified as ECOG 0-1. Each patient received oxaliplatin as a first line treatment. Also prior use of bevacizumab was reported in 12 patients (60%) and anti-EGFR in 5 patients (25%). 70% of them had mutated RAS status and 30% wild-type RAS status.. The median number of cycles given was 10 (2-42). Aflibercept dose reduction was required in 6 patients (30%), and therapy discontinuation due to toxicity in 2 (10%), 1 as a consequence of hypertension and 1 as diarrhea. In all patients, some kind of grade treatment-related adverse events occurred. Most frequently 3-4 grade toxicity observed were: asthenia (20%), neutropenia (20%), hypertension (20%), diarrhea (15%), stomatitis (15%), palmar-plantar erythrodysesthesia (10%) and proteinuria (5%).. In patients evaluable for response, the response rate was 40% and the disease control rate of 73%. In a follow-up median time of 9 months, the progression-free survival median time was 6,5 months (2-23), and ...
Data on 2281 participants from eight RCTs were available from reports of single-agent doxorubicin versus doxorubicin-based combination chemotherapy. Meta-analysis using the fixed effect model detected a higher tumour response rate with combination chemotherapy compared with single-agent chemotherapy (odds ratio [OR= 1.29; 95% confidence interval [CI], 1.03 to 1.60; p = 0.03), but the OR from a pooled analysis using the random effects model and the same data did not achieve statistical significance (OR= 1.26; 95% CI, 0.96 to 1.67; p = 0.10). No significant difference between the two regimens was detected in the pooled one-year mortality rate (OR = 0.87; 95% CI, 0.73 to 1.05; p=0.14) or two-year mortality rate (OR = 0.84; 95% CI, 0.67 to 1.06; p=0.13) (N=2097). Although reporting of adverse effects was limited and inconsistent among trials (making pooling of data for this outcome impossible), adverse effects such as nausea/vomiting and hematologic toxic effects were consistently reported as being ...
Chemotherapy is a systemic method of cancer treatment, in contrast with local therapies such as surgery and radiation therapy. The drugs used in chemotherapy are able to reach most parts of the body. Therefore, chemotherapy is likely to be recommended for cancer that has already spread to other areas of the body, for tumors that occur at more than one site, or for tumors that cannot be removed surgically. It is also used when a patient has recurrent disease after initial treatment with surgery or radiation therapy.. Chemotherapy is less mutilating than surgery and helps conserve organ or limb function since anti-cancer drugs are used to act on cancer cells without direct removal of a body part.. For some cancers, chemotherapy alone can destroy all the cancer cells and cure the cancer (primary treatment). As an adjuvant treatment, chemotherapy is given prior to, or after other methods, to increase the effectiveness of cancer treatment. Most often, adjuvant chemotherapy is given after other ...
Nausea and vomiting are common side effects of chemotherapy drugs that are used to treat cancer. Some chemotherapy drugs are worse offenders than others In most cases, patients will be given anti-vomiting (antiemetics) and anti-nausea medication prior to the administration of chemotherapy. Some of the commonly used antiemetics are listed in the chart below. As you can see, these drugs may also have some side effects of their own.
This paper considers the consensus problem of nonlinear multi-agent systems under switching directed topologies. Specifically, the dynamics of each agent incorporates an intrinsic nonlinear term and the interaction topology may not contain a spanning tree at any time. By designing a state-controlled switching law, we show that the multi-agent system with the neighbor-based protocol can achieve consensus if the switching topologies jointly contain a spanning tree. Moreover, an easily manageable algebraic criterion is deduced to unravel the underlying mechanisms in reaching consensus. Finally, a numerical example is exploited to illustrate the effectiveness of the developed theoretical results.
Roche noted that a Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death (PFS) compared to Avastin plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small cell lung cancer (NSCLC). Initial observations for the co-primary endpoint of overall survival (OS) are encouraging. These data are not fully mature and the next OS analysis is expected in the first half of 2018. Safety for the TECENTRIQ and Avastin plus chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination ...
Eliminating pro-inflammatory cells after treatment relieves symptoms in mice.. January 17, 2017/Novato, California: Standard chemotherapy is a blunt force instrument against cancer - and its a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body. Researchers at the Buck Institute and elsewhere now show that chemotherapy triggers a pro-inflammatory stress response termed cellular senescence, promoting the adverse effects of chemotherapy as well as cancer relapse and metastasis. Eliminating the senescent cells in mice prevented the side effects and relapse. The research is published in Cancer Discovery.. "While chemotherapy does save lives, it often comes with a very high price," said Judith Campisi, PhD, Buck faculty and senior scientist on the study. "Our work in mice studied the effects of chemotherapy on cancer relapse and other serious side effects. It provides a ...
Median follow-up was 16.1 months (5.1-39.0) in the FOLFOX-FOFIRI regimen and 19.9 months (4.0-46.6) in the XELOX-XELIRI regimen. Ten patients were treated with bevacizumab in either a first or second setting in the FOLFOX-FOFIRI regimen, whereas 20 patients were treated with bevacizumab in the XELOX-XELIRI regimen. In the first-line chemotherapy, DCR was 85.0% in the FOLFOX regimen and 58.5% in the XELOX regimen, whereas, in the second-line chemotherapy, DCR was 50.0% in the FOLFIRI regimen and 41.4% in the XELIRI regimen. In the first-line chemotherapy, the median PFS was 6.5 months in the FOLFOX regimen and 6.0 months in the XELOX regimen (p = 0.127). In the second-line chemotherapy, the median PFS was 4.6 months in the FOLFIRI regimen and 4.0 months in the XELIRI regimen (p = 0.370). The median OS was 24.5 months in the FOLFOX-FOFIRI regimen and 23.2 months in the XELOX-XELIRI regimen (p = 0.994). The median TI was 14.0 months in the FOLFOX-FOFIRI regimen and 12.0 months in the XELOX-XELIRI ...
For women with early-stage breast cancer who are receiving chemotherapy, shortening the time between treatment cycles or administering the agents sequentially may reduce disease recurrence and mortality compared with standard chemotherapy regimens.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from an ongoing Phase 1b clinical trial evaluating the companys lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with paclitaxel (Taxol®), a standard chemotherapy regimen, in patients with metastatic breast cancer.
1573 PURPOSE: Ovarian cancer is the leading cause of death in patients diagnosed with gynecologic cancers. This is due in part to the late stage at diagnosis as well as the development of chemotherapy resistance. Ovarian cancer is commonly treated with debulking surgery followed by adjuvant platinum/taxane-based chemotherapy combinations. To prevent chemotherapy-related side effects, synthetic glucocorticoids (GCs) such as dexamethasone (DEX) are routinely given with cytotoxic therapy. Of concern, pre-clinical data implicate GCs in inhibiting apoptosis in epithelial tumors such as breast and ovarian cancers, and therefore in resistance to chemotherapy. These effects are thought to be mediated by upregulation of pro-cell survival genes including Serum and Glucocorticoid-regulated Kinase (SGK). SGK encodes SGK-1, a serine/threonine kinase that shares 54% homology with the catalytic domain of protein kinase B (PKB/Akt) and has been shown to be overexpressed in a variety of cancers. Despite abundant ...
The oncologist will also determine how long and how often you will have chemotherapy treatments. Chemotherapy can be given intravenously (in the vein or IV) or by pill, and usually a combination of drugs is used. Chemotherapy treatments are often given in cycles; a treatment for a period of time, followed by a recovery period, then another treatment. Chemotherapy may be given in a variety of settings including your home, a hospital outpatient facility, a doctors office or clinic, or in a hospital.. Chemotherapy can be given before surgery to shrink the tumor and sometimes make breast conserving surgery possible rather than a mastectomy. Many times it is given after surgery and may be given every three weeks or every two weeks in a "dose dense" fashion.. ...
TY - JOUR. T1 - Temporal differences in coping, mood, and stress with chemotherapy. AU - Chernecky, Cynthia C. PY - 1999/8/1. Y1 - 1999/8/1. N2 - This longitudinal study examined relations among mood, coping, perceived stress, and side effects from chemotherapy in 50 individuals with stages III and IV adenocarcinoma of the lung over four consecutive combination chemotherapy courses. Results indicated that perceived stress was moderately high only at the time of pretreatment, and four coping strategies were used: seeking social support, planful problem solving, self-control, and positive reappraisal. No relations existed between coping strategies and side effects from chemotherapy, coping and perceived stress, mood and side effects, and perceived stress and side effects. Seven side effects occurred: leukopenia, decreased activity, nausea, loss of appetite, fatigue, constipation, and taste changes. In summary, receiving chemotherapy is stressful at the time of pretreatment, so nursing ...
Biweekly chemotherapy treatment -- a dose-dense regimen -- for patients with early-stage breast cancer was found to be as safe as treatment administered every third week; however, the dose-dense regimen did not result in improvements in recurrence or survival, according to a study in the December 7 issue of the Journal of the National Cancer Institute.
Patients with MDS who are unable or unwilling to undergo a stem cell transplant using donor cells or those planning to have their own stem cells collected for a future transplant can receive conventional chemotherapy without stem cell support. While many patients have a remission with this type of treatment, most ultimately experience disease progression. While some patients may experience a long remission following therapy, remissions after conventional chemotherapy typically average less than 12 months.. Because most patients with MDS are over 65 years of age and cannot tolerate the side effects of conventional chemotherapy, lower doses of chemotherapy may be beneficial.. Vidaza® (azacitadine): In May of 2004, the U.S. Food and Drug Administration (FDA) approved Vidaza for the treatment of MDS. Vidaza is the first drug to be approved specifically for the treatment of MDS.. Results of a clinical trial that compared Vidaza to supportive care in the treatment of 191 patients with MDS ...
While there is some evidence from different other, mostly retrospective, trials reporting a benefit from continued trastuzumab treatment beyond disease progression with a changed chemotherapy regimen only [22-24], a discontinuation after disease progression is still standard of care. Though the here presented study is limited by the relatively small number of patients included, we are clearly able to strengthen existing evidence that there is a benefit for at least some patients.. The reported decline in response rates from 42.6% in first line treatment to 30% in beyond second line compares to the expected drop of response rates with every further line of chemotherapy or endocrine therapy in palliative treatment. Stable disease and objective response combined, clinical benefit rates were 85.2% in first line, 68.5% in second line and 58.3% in beyond second line. As some other groups, we believe this to be the more significant parameter in judging the efficacy of palliative treatment, as a ...
Inclusion Criteria: - The subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+ - The subject has AR+ breast cancer - The subject has metastatic disease or has locally advanced disease that is not amendable to curative treatment - The subject has measurable disease or nonmeasurable, evaluable disease per RECIST 1.1. (NOTE: pleural effusions, ascites or other third fluid space are not evaluable diseases per RECIST 1.1). - The subject has received at least 1 line of therapy in the metastatic or locally advanced disease setting. The subject has been documented to have progressed by determination of the investigator on a regimen containing an anti-HER2 agent as the most recent regimen or the most recent anti-HER2 regimen was discontinued for any toxicity, with the exception of a cardiotoxicity. - The subject has adequately recovered from toxicities due to prior therapy. - The subject has an Eastern Cooperative Oncology Group performance (ECOG) status ≤ 1 at ...
This purpose of this study is to evaluate the safety and tolerability of study drug atezolizumab when administered with bevacizumab and FOLFOX in patients with gastric cancer. This study will also evaluate the safety and tolerability of atezolizumab administered with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
The Cochrane review by Jones and colleagues clearly shows that overall survival and progression-free survival are not improved by adding extra cytotoxic drugs to an existing regimen (≥ 2 drugs) in women having first-line chemotherapy for metastatic breast cancer. Toxicities, such as leukopenia, nausea, vomiting, and alopecia, were increased, as were rates of tumor shrinkage. More recent trials comparing 1- and 2-drug combinations had similar findings (1). All trials in this review were published before 1992, which limits the direct applicability of the results to current practice. The trials did not include newer agents, such as the taxanes, or targeted drugs, such as trastuzumab and bevacizumab. More recent trials of newer agents have generally tested their addition to a single drug, and trials of that design were not eligible for this review. For example, the addition of capecitabine to docetaxel improved response rates, time to progression, and overall survival, but also increased toxicity ...
During high-dose chemotherapy, the patient receives high doses of chemotherapy, and possibly radiation therapy, in order to kill the cancer cells. Whi
The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group (ECOG) for 37 years. This application is submitted to request funding via the U10 me...
Word Scramble - English word CHEMOTHERAPY: words that start with chemotherapy, words that end with chemotherapy, anagrams of chemotherapy, how to spell chemotherapy!, Words with Friends, Scrabble
Scientists have been able to identify the group of children needing more intensive, aggressive chemotherapy treatment for the most common form of brain cancer - Featured https://debuglies.com
Short-term side effects occur because many chemotherapy drugs act on normal cells as well as cancer cells. Fast growing cells are the most affected. This includes cells that make up hair, skin, the digestive tract and blood. Chemotherapy can also affect certain other cells, such as those in the nervous system and organs (such as heart, kidneys, liver and lungs). They may also impact fertility. Some chemotherapy drugs may have long-term effects. For example, another cancer could occur at a later time as a result of taking chemotherapy. If you have any questions regarding this matter, please ask your doctor or nurse.. ...
Results Physicians and nurses reported trying to inform patients fully about their poor prognosis and treatment options. They would carefully consider the (side) effects of chemotherapy and sometimes doubted whether further treatment would contribute to patients quality of life. Both groups considered the patients wellbeing to be important, and physicians seemed inclined to try to preserve this by offering further chemotherapy, often followed by the patient. Nurses were more often inclined to express their doubts about further treatment, preferring to allow patients to make the best use of the time that is left. When confronted with a treatment dilemma and a patients wish for treatment, physicians preferred to make compromises, such as by "trying out one dose." Discussing death or dying with patients while at the same time administering chemotherapy was considered contradictory as this could diminish the patients hope.. ...
Read about how chemotherapy affects your blood cells, which can lead to side effects such as infections or feeling tired and weak (anaemia).
The Hoosier Oncology Group has recently activated a phase III FFilagra of PTK787 in combination with trastuzumab in patients with newly diagnosed Ffrom overexpressing, locally recurrent, or metastatic breast cancer. p.
h2,Why does my child need chemotherapy?,/h2,,p,Chemotherapy will help treat your childs brain tumour. The treatment team is led by a doctor called a neuro-oncologist. They take the responsibility for your childs care during chemotherapy, and makes the decisions about your childs treatment plan.,/p,,p,Here are possible reasons why chemotherapy may be given:,/p,,ul,,li, To cure the tumour: With some types of brain tumours, chemotherapy can destroy all the tumour cells. ,/li,,li, To control the tumour: Chemotherapy may be given after surgery to destroy any tumour that was left behind, or other tumour cells that are too small to see. This is to try and stop the tumour from growing again. It will also stop it from spreading to other parts of the brain or spine. ,/li,,li, To improve quality of life: If a cure is not possible, chemotherapy may be given to reduce symptoms.,/li,,/ul,,h2,How is chemotherapy given?,/h2,,p,There are many different types of chemotherapy medicines. Each drug acts in a ...
Chemotherapy side effects depend on the chemotherapy treatment as there are varied types of chemotherapy medications. Traditional chemotherapy drugs kill growing cancer cells.
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If youre eligible to participate, you may be contacted by a nurse or study coordinator. If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate. In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile. ...
Doctors and pharmaceutical companies make money from it. Thats the only reason chemotherapy is still used. Not because its effective, decreases morbidity, mortality or diminishes any specific cancer rates. In fact, it does the opposite....
AC-T or AC-Taxol is a chemotherapy combination treatment used to treat breast cancer. Learn more about the medicines it contains and the treatment itself here.
The GND chemotherapy regimen is an alternative chemotherapy treatment. Current data is developing, but preliminary results indicate it is a relatively successful treatment for Hodgkins lymphoma.
Every year in the United Kingdom, 200,000 people are diagnosed with cancer and 152,500 people die. In the United States, the annual death rate for this disease is approxi¬mately 547,000. These deaths are recorded as cancer deaths, but how many of these deaths are really attributable to the disease itself? How many deaths should in fact be recorded as "death by doctoring"? When we consider that conventional treatment consists almost entirely of radiation, chemotherapy and the long-term application of toxic pharma-ceuticals-treatments which are all well known for their life-threatening side-effects- then the question becomes all the more legitimate. On chemotherapy, for instance, note the following: "Most cancer patients in this country die of chemotherapy. Chemotherapy does not eliminate breast, colon, or lung cancers. This fact has been documented for over a decade, yet doctors still use chemotherapy for these tumors." (Allen Levin, MD, UCSF, The Healing of Cancer, Marcus Books, 1990 ...